Thermo Fisher Scientific Opens Dry Powder Media Facility in Singapore
Singapore facility delivers manufacturing redundancy and increases supply assurance for global biologic drug discovery and production.
Thermo Fisher Scientific Inc. announced it is expanding its global cell culture and bioprocessing capabilities by opening a new manufacturing plant in Singapore to produce dry powder media (DPM),a crucial cell culture raw material used to manufacture biologics, including vaccines, anticancer therapeutics, and others. The facility is the first cell culture DPM production site in Singapore and is designed to address the increased global requirements from biopharmaceutical companies to mitigate critical raw material supply risks, the company reports.
Located in Tuas, the 30,800 ft2 facility will provide manufacturing redundancy of DPM to help ensure a secure and uninterrupted supply to biopharmaceutical customers globally, according to a company statement. The facility will also serve as an additional logistics hub for DPM distribution to Asia Pacific customers.
Featuring state-of-the-art pin milling technology, the new Singapore DPM facility is a cGMP manufacturing plant, mirroring the functionality and quality systems used in Thermo Fisher’s DPM facility in the United States.
Source: Thermo Fisher Scientific
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
